Industry Update: the Latest Developments in Therapeutic Delivery

• Halfdanarson TR , RabeKG, RubinJet al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 19, 1727–1733 (2008).
   PubMed Web of Science ®Google Scholar
• Raymond E , DahanL, RaoulJLet al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501–513 (2011).
   PubMed Web of Science ®Google Scholar
• De Bono JS , LogothetisCJ, MolinaAet al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
   PubMed Web of Science ®Google Scholar
• Chapman PB , HauschildA, RobertCet al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
   PubMed Web of Science ®Google Scholar
• Robert C , ThomasL, BondarenkoIet al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
   PubMed Web of Science ®Google Scholar
• Peck AR , WitkiewiczAK, LiuCet al. Loss of nuclear localized and tyrosine phosphorylated STAT5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J. Clin. Oncol. 29, 2448–2458 (2011).
   PubMed Web of Science ®Google Scholar
• Schuster SJ , NeelapuSS, GauseBLet al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29, 2787–2794 (2011).
   PubMed Web of Science ®Google Scholar
• Kardava L , MoirS, WangWet al. Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J. Clin. Invest. 121, 2614–2624 (2011).
   PubMed Web of Science ®Google Scholar

Patents

• Winssinger N, Barluenger S, Karplus M. US0146545A1 (2008).
   Google Scholar
• Schneider M, Gottfreid M, Geisler J et al. US0056585A1 (2010).
   Google Scholar

Websites

• Merck completes acquisition of Inspire Pharmaceuticals, Inc. www.merck.com/newsroom/news-release-archive/corporate/2011_0516.html
   Google Scholar
• Merck Sharpe and Dohme completes Inspire takeover. www.zenopa.com/news_story.php?id=800535886
   Google Scholar
• Radius, 3M Drug Delivery Systems sign development agreement for transdermal drug delivery of BA058 for treatment of osteoporosis. http://solutions.3m.com/wps/portal/3M/en_WW/DrugDeliverySystems/DDSD/about-3M-Drug-Delivery/news/?PC_7_RJH9U5230O73F02RQG9R9E1OH0_assetId=1273684518958
   Google Scholar
• Sanofi and Glenmark Pharmaceuticals sign license agreement on novel monoclonal antibody for Crohn‘s disease and other chronic autoimmune disorders. http://en.sanofi.com/binaries/20110516_GLENMARK_en_tcm28–32720.pdf
   Google Scholar
• Glenmark Pharmaceuticals out-licenses novel monoclonal antibody, GBR500, to Sanofi. www.prnewswire.com/news-releases/glenmark-pharmaceuticals-out-licenses-novel-monoclonal-antibody-gbr-500-to-sanofi-121889273.html
   Google Scholar
• AVEO Pharmaceuticals enters into worldwide license agreement with Centocor Ortho Biotech to develop and commercialize RON-targeted antibodies. http://investor.aveopharma.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=1568940&highlight=
   Google Scholar
• Bristol-Myers Squibb and Roche enter into a clinical collaboration agreement to conduct combination studies with Yervoy™ (ipilimumab) and vemurafenib. www.bms.com/news/press_releases/pages/default.aspx
   Google Scholar
• Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer. www.roche.com/media/media_releases/med-cor-2011–2006–02.htm
   Google Scholar
• US FDA approves Yervoy (ipilimumab) for the treatment of patients with newly diagnosed or previously treated unresectable or metastatic melanoma, the deadliest form of skin cancer. www.bms.com/news/press_releases/pages/default.aspx
   Google Scholar
• Affectis Pharmaceuticals and Merck Serono announce an agreement to develop oral drugs for neurodegenerative diseases. www.affectis.com/attachments/030_Affectis-Merck%20Press%20Release%20080611_english.pdf
   Google Scholar
• Merck and Hanwha Chemical Corporation establish global strategic collaboration to develop and commercialize biosimilar candidate. www.merck.com/newsroom/news-release-archive/research-and-development/2011_0613.html
   Google Scholar
• Vertex and Alios BioPharma announce exclusive worldwide licensing agreement for two new nucleotide drug candidates, broadening Vertex‘s efforts to develop new combinations of medicines for hepatitis C. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=584023
   Google Scholar
• FDA approves Incivek™ for hepatitis C. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm
   Google Scholar
• FDA approves Edurant™ (rilpivirine) for use in treatment-naive adults with HIV-1. www.jnj.com/connect/news/all/fda-approves-edurant-rilpivirine-for-use-in-treatment-naive-adults-with-hiv-1
   Google Scholar
• FDA approves new HIV treatment. www.prnewswire.com/news-releases/fda-approves-new-hiv-treatment-122329203.html
   Google Scholar
• Sutent® receives FDA approval for advanced pancreatic neuroendocrine tumors. www.pfizer.com/news/press_releases/pfizer_press_releases.jsp#guid=20110520006117en&source=RSS_2011&page=2
   Google Scholar
• FDA approves Incivek (telaprevir) for people with hepatitis C. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=580154
   Google Scholar
• FDA approves Incivek for hepatitis C. www.prnewswire.com/news-releases/fda-approves-incivek-for-hepatitis-c-122441703.html
   Google Scholar
• Abbott receives FDA approval for Xience nano™ to treat coronary artery disease in small vessels. www.abbott.com/PressRelease/2011May24.htm
   Google Scholar
• FDA approves Nulojix® for kidney transplant patients. www.prnewswire.com/news-releases/fda-approves-nulojix-for-kidney-transplant-patients-123944799.html
   Google Scholar
• FDA approves Nulojix (belatacept). www.bms.com/news/press_releases/pages/default.aspx?RSSLink=; http://www.businesswire.com/news/bms/20110616006683/en&t=634438393397918958
   Google Scholar
• Pivotal Phase 3 study published in The New England Journal of Medicine finds overall survival of patients with metastatic castration-resistant prostate cancer is significantly improved with Zytiga™ (abiraterone acetate). www.jnj.com/connect/news/all/phase-3-study-published-in-the-new-england-journal-of-medicine-finds-survival-of-patients-with-metastatic-castration-resistant-prostate-cancer-is-improved-with-zytiga
   Google Scholar
• Zytiga (abiraterone acetate) receives FDA approval for treatment of metastatic prostate cancer after priority review. www.jnj.com/connect/news/all/zytiga-abiraterone-acetate-receives-fda-approval-for-treatment-of-metastatic-prostate-cancer-after-priority-review
   Google Scholar
• Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations. www.roche.com/media/media_releases/med-cor-2011–2006–05.htm
   Google Scholar
• Plexxikon reports positive data from Phase 3 and Phase 2 trials of vemurafenib (PLX4032). www.daiichisankyo.com/news/detail/004093.html
   Google Scholar
• Genentech announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations. http://us1.campaign-archive2.com/?u=a79342281b0477b9894fca9da&id=36ce7d899e&e=9ea83021c8
   Google Scholar
• Second Phase III study of Yervoy (ipilimumab) in metastatic melanoma meets primary end point of overall survival. www.bms.com/news/press_releases/pages/default.aspx
   Google Scholar
• Merck and ARIAD announce presentation of results of Phase III SUCCEED trial at American Society of Clinical Oncology Annual Meeting. www.merck.com/newsroom/news-release-archive/research-and-development/2011_0606.html
   Google Scholar
• US patent granted for a new family of heat shock protein 90 (Hsp90) inhibitors for the treatment of cancer and neurodegenerative indications. www.nexgenixpharm.com/press/pr-2011–2005–19.html
   Google Scholar
• Syndax Pharmaceuticals announces issuance of US patent for entinostat. www.syndax.com/assets/110601_US_Patent.pdf
   Google Scholar
• Syndax Pharmaceuticals‘ entinostat plus erlotinib improves survival in select NSCLC patients. www.syndax.com/assets/12_9_10_ASTRO_Tarceva_plus_entinostat_shows_survival_advantage.pdf
   Google Scholar
• Marker identifies breast cancer patients likely to respond to tamoxifen. http://blog.kimmelcancercenter.org/?p=1884
   Google Scholar
• Vaccine increases disease-free survival for follicular lymphoma patients. www.medicalnewstoday.com/releases/227015.php
   Google Scholar
• NIH scientists reactivate immune cells exhausted by chronic HIV. www.niaid.nih.gov/news/newsreleases/2011/pages/sirna.aspx
   Google Scholar